|Bid||0.9836 x 2200|
|Ask||0.9900 x 1400|
|Day's Range||0.9400 - 1.0050|
|52 Week Range||0.6200 - 11.1800|
|Beta (5Y Monthly)||1.86|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 24, 2022 - Aug 29, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||12.50|
Long term investing is the way to go, but that doesn't mean you should hold every stock forever. We really hate to see...
RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, announced the upcoming presentation of new Talicia® H. pylori eradication data as well as publication and presentation of data from the opaganib and RHB-107 (upamostat) late clinical-stage COVID-19 programs at important medical congresses in July and August, 2022.
The drugmaker is cutting one-third of its U.S. commercial workforce as part of a plan to save $50 million. The move comes as the biotech industry sees cuts across the board as the highs of the pandemic fade away.